As of 2025-03-16, the EV/EBITDA ratio of Summit Therapeutics Inc (SMMT) is -26.48. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SMMT's latest enterprise value is 15,226.72 mil USD. SMMT's TTM EBITDA according to its financial statements is -575.12 mil USD. Dividing these 2 quantities gives us the above SMMT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-03-07 | -23.61 |
| 2025-03-06 | -24.17 |
| 2025-03-05 | -24.89 |
| 2025-03-04 | -24.30 |
| 2025-03-03 | -24.35 |
| 2025-02-28 | -26.35 |
| 2025-02-27 | -23.53 |
| 2025-02-26 | -23.28 |
| 2025-02-25 | -23.04 |
| 2025-02-24 | -23.98 |
| 2025-02-21 | -28.18 |
| 2025-02-20 | -29.39 |
| 2025-02-19 | -27.51 |
| 2025-02-18 | -26.85 |
| 2025-02-14 | -27.22 |
| 2025-02-13 | -27.80 |
| 2025-02-12 | -24.91 |
| 2025-02-11 | -24.28 |
| 2025-02-10 | -26.10 |
| 2025-02-07 | -25.60 |
| 2025-02-06 | -26.32 |
| 2025-02-05 | -26.46 |
| 2025-02-04 | -26.26 |
| 2025-02-03 | -25.44 |
| 2025-01-31 | -27.39 |
| 2025-01-30 | -28.49 |
| 2025-01-29 | -27.57 |
| 2025-01-28 | -29.95 |
| 2025-01-27 | -29.98 |
| 2025-01-24 | -30.28 |
| 2025-01-23 | -31.43 |
| 2025-01-22 | -29.98 |
| 2025-01-21 | -28.16 |
| 2025-01-17 | -24.22 |
| 2025-01-16 | -23.14 |
| 2025-01-15 | -23.15 |
| 2025-01-14 | -21.17 |
| 2025-01-13 | -23.12 |
| 2025-01-10 | -22.71 |
| 2025-01-08 | -23.95 |
| 2025-01-07 | -23.10 |
| 2025-01-06 | -22.22 |
| 2025-01-03 | -23.21 |
| 2025-01-02 | -23.35 |
| 2024-12-31 | -22.70 |
| 2024-12-30 | -22.76 |
| 2024-12-27 | -23.17 |
| 2024-12-26 | -24.54 |
| 2024-12-24 | -24.18 |
| 2024-12-23 | -23.76 |